Hemab Therapeutics Holdings, Inc. Common Stock (COAG) vs GH Research PLC (GHRS)

A side-by-side comparison of Hemab Therapeutics Holdings, Inc. Common Stock and GH Research PLC across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Hemab Therapeutics Holdings, Inc. Common Stock logo
COAG
Hemab Therapeutics Holdings, Inc. Common Stock
$1.42B
$30.37HealthcareDelayed quote: Oct 6, 2026, 9:35 AM EDT
GH Research PLC logo
GHRS
GH Research PLC
$1.51B
$21.98HealthcareDelayed quote: Oct 6, 2026, 9:35 AM EDT

Total return — COAG vs GHRS

growth of $100 · dividends reinvested · last 1y
COAG -10.0% (-10.0%/yr)GHRS +8.0% (+8.0%/yr)GHRS compounded faster over this window
80100120140160Start $100$90$108
COAG GHRS

COAG vs GHRS: by the numbers

  • •GHRS is the larger company ($1.51B vs $1.42B market cap).

Metrics side by side

Valuation

MetricCOAGGHRS
P/B ratio3.124.19

Profitability

MetricCOAGGHRS
Gross margin0.00%0.00%
Operating margin0.00%0.00%
Net margin0.00%0.00%
ROEN/A-17.32%
ROIC-38.09%-19.87%

Growth (annualized)

MetricCOAGGHRS
Total return CAGR (5Y)N/A0.52%

Go deeper

Full COAG analysisFull GHRS analysisInteractive comparison tool

Dig into the metrics

Hemab Therapeutics Holdings, Inc. Common Stock ROEGH Research ROEHemab Therapeutics Holdings, Inc. Common Stock operating marginGH Research operating marginHemab Therapeutics Holdings, Inc. Common Stock revenue growthGH Research revenue growthHemab Therapeutics Holdings, Inc. Common Stock free cash flowGH Research free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.